Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
Zemansky noted that Keros has wrapped up its strategic review, with the board deciding to advance KER-065 for Duchenne muscular dystrophy (DMD) and return $375 million in excess capital to shareholders.
The analyst highlights that the stock has been downgraded not due to concerns about the platform or pipeline, which remains compelling, but because of limited near-term upside.Despite favorable valuation and a solid cash buffer, Zemansky writes that the stock may stay range-bound given that meaningful updates on KER-065 are unlikely soon, with FDA discussions not expected until the third quarter. As a result, other investment opportunities may offer better near-term potential.
The analyst slashed the price forecast to reflect adjustments to the cash balance and a higher weighted average cost of capital (WACC) of 16%, now aligned with peers at a similar stage.
On June 9, 2025, ADAR1 Capital Management, the largest shareholder of Keros Therapeutics, stated that the recent board election results signal 'widespread dissatisfaction' among investors. ADAR1 highlighted that two directors received support from only about a third of outstanding shares, reflecting a loss of confidence in the board's management and capital allocation.
While acknowledging Keros's recent decision to halt a drug program and cut staff, ADAR1 called the actions 'wholly insufficient.' The firm heavily criticized the board's plan to return only a portion of its cash to shareholders, arguing the amount retained is excessive for Keros's limited clinical pipeline.
To address this, ADAR1 issued specific demands for the board to take immediate action. The firm called for Keros to increase its capital return by an additional $100 million for a total of $475 million, to be paid through a special dividend by the end of Q3 2025.
Furthermore, ADAR1 urged the company to create a contingent value right (CVR) to allow shareholders to directly benefit from the Takeda partnership. ADAR1 warned that if the board does not adopt a more aggressive, investor-focused strategy, it will not hesitate to nominate new directors for the 2026 annual meeting to ensure the will of shareholders is respected.
Zemansky acknowledged that the board had limited strategic options aside from fully dissolving the company. However, he writes that bearish investors may have expected a more aggressive outcome than just the potential $375 million capital return, especially since the exact structure and terms of the buyback remain undecided.
Zemansky pointed out that beyond the longer development timelines, overall sentiment toward Keros likely remains cautious, which could continue to pressure the stock.
While the company's three board nominees were elected despite activist opposition, a notable portion of votes were withheld for the two targeted candidates, indicating lingering investor discontent.
He stresses the point that frustration may persist, particularly given the recent setback with TROPOS and skepticism that last month's cost-cutting measures were sufficient.
Although some bulls might argue that the stock has been unfairly punished, especially given the added hurdles of developing drugs that target the TGF-β pathway, Zemansky writes most investors will likely wait for more meaningful progress and risk reduction before 'returning to the story.'
Price Action: KROS shares are trading lower by 2.34% to $13.76 at last check Tuesday.
Read Next:Image via Shutterstock
Date
Firm
Action
From
To
Dec 2020
SVB Leerink
Maintains
Outperform
Dec 2020
HC Wainwright & Co.
Maintains
Buy
May 2020
Piper Sandler
Maintains
Overweight
View More Analyst Ratings for KROS
View the Latest Analyst Ratings
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
This article Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
22 minutes ago
- Business Insider
Alibaba (BABA) vs. Amazon (AMZN): Which E-Commerce Stock Has More Upside Ahead of Q2 Earnings?
The second-quarter earnings season is in full swing, and investors are closely watching global e-commerce leaders like Amazon (AMZN) and Alibaba (BABA) to assess the strength of consumer demand, the outlook for digital retail, and their growing role in artificial intelligence. Using TipRanks' Stock Comparison Tool, we will compare these two tech-powerhouse stocks to find the better pick ahead of the upcoming earnings results, according to Wall Street analysts. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alibaba (NYSE:BABA) Stock Alibaba is China's largest e-commerce and cloud services company, operating platforms like Taobao, Tmall, and AliCloud. The stock has climbed over 39% so far this year, driven by strong gains in its AI-powered cloud services and growing demand for instant delivery. The company is doubling down on artificial intelligence, aiming to use it to transform online shopping and cloud services. It is using AI across its apps and cloud platform to improve customer experience and stay ahead of the competition. Looking ahead, the company is set to report its Q1 FY26 earnings next month. Wall Street expects Alibaba to report earnings of $2.22 per share for Q1, down 3% from the year-ago quarter. The decline could be due to the company's heavy investment in logistics and delivery. Meanwhile, analysts project Q1 revenues at $35.46 billion, up 6% year-over-year. Is Alibaba Stock a Good Buy Right Now? Ahead of the Q1 results, Benchmark's Top analyst Fawne Jiang reiterated her Buy rating with a $176 price target, implying a 47% gain from current levels. The analyst sees recent share weakness as a 'buying opportunity' and encourages investors to 'build exposure on dips,' confident in Alibaba's strong long-term growth outlook. Nevertheless, she expects Alibaba's margins and profits to come under pressure in the near term due to increased spending. As a result, Benchmark has cut its EBITDA forecast to RMB44 billion for Q1 FY26 and RMB208 billion for the full FY26, 'reflecting near-term margin pressure.' Overall, Wall Street has a Strong Buy consensus rating on Alibaba stock based on 14 Buys and one Hold rating. The average Alibaba price target of $151.08 implies about 26% upside potential from current levels. Amazon (NASDAQ:AMZN) Stock E-commerce and cloud computing giant Amazon is proving the resilience of its business model despite macro challenges and tariff woes. The stock has climbed over 5% so far this year. Several analysts remain bullish on Amazon's high-margin cloud unit, Amazon Web Services (AWS), which is expected to benefit from growing AI demand. In Q1 2025, AWS accounted for just 19% of revenue but delivered an impressive 63% of total operating profit. Meanwhile, Amazon's fast-expanding advertising segment is also emerging as a key growth engine. Looking ahead, Amazon is scheduled to announce its second-quarter results on July 31. Wall Street projects a 9% growth in Amazon's revenue to $162 million. Meanwhile, analysts expect the company to report earnings per share of $1.32 compared to $1.26 in the prior-year quarter. Is Amazon a Buy, Hold, or Sell? Ahead of the Q2 print, BofA Securities analyst Justin Post raised his price target to $265, up from $248, while maintaining a Buy rating. Post expects Amazon's Q2 retail performance to be strong, helped by positive credit card spending data and an extended Prime Day. He also believes AWS is picking up pace, with a strong order backlog and rising cloud demand. The analyst now predicts Q2 revenue of $164 billion, above Wall Street's estimate of $162.1 billion. Turning to Wall Street, AMZN stock has a Strong Buy consensus rating based on 44 Buys and one Hold assigned in the last three months. At $258.27, the average Amazon stock price target implies an 11.59% upside potential. Conclusion Ahead of earnings, Wall Street remains bullish on both Alibaba and Amazon stocks. However, analysts see greater upside potential in Alibaba, supported by its strong fundamentals, expanding AI initiatives, and solid recovery in e-commerce business. Meanwhile, Amazon is gaining from steady growth in cloud and advertising, two high-margin areas set to benefit from AI. While its upside may be smaller than Alibaba's, Amazon's stable growth and strong cash flow continue to earn Wall Street's confidence.
Yahoo
28 minutes ago
- Yahoo
1 Super Artificial Intelligence (AI) Stock Billionaire Bill Gates Has 25% of His Foundation's Portfolio Invested In
Key Points The Gates Foundation holds a substantial number of Microsoft shares. Microsoft has become a top player in offering artificial intelligence models. However, the stock is starting to appear somewhat pricey compared to its peers. 10 stocks we like better than Microsoft › Bill Gates is a well-known entrepreneur, having co-founded Microsoft (NASDAQ: MSFT) in the mid-1970s. This made him a fortune, and he constantly ranks among the richest people in the world. He established the Gates Foundation Trust, one of the world's most well-funded foundations. By examining its holdings, investors can gain insight into what one of the world's brightest minds considers top stock picks, and they've identified an AI stock that has been a stellar performer in recent years. In fact, the stock has more than doubled since the start of 2023 alone. What is this stock? It's none other than Microsoft. Microsoft is the foundation's top holding This really shouldn't come as a surprise to anyone. Bill Gates runs the fund, so he will fill it with a company that he thinks will succeed. Most of this stock was donated from Gates' wealth; however, if the foundation didn't think Microsoft was set to succeed, they would have sold it a long time ago and moved on to something else. About 25% of the foundation's worth is tied up in Microsoft stock, valued at around $10.7 billion. That's a concentrated bet for a charitable foundation, but it has worked out well with Microsoft's recent success. Microsoft has emerged as a top AI pick due to its role as a facilitator in the space. It isn't developing its own generative AI model; instead, it's offering many of the leading ones on its cloud computing platform, Azure. Developers can choose from OpenAI's ChatGPT, a leading option, Meta Platforms' Llama, DeepSeek's R1 (a more affordable alternative from China), or xAI's Grok, a company founded by Elon Musk. By offering a wide range of generative AI models, Microsoft isn't locking its clients into a single provider. This has made Azure a top choice for building AI models on, which is why it has outgrown its peers in recent quarters. We'll get an update on how the other cloud computing providers -- namely Alphabet's Google Cloud and Amazon's Amazon Web Services (AWS) -- in the next few weeks, but I'd be shocked if Azure isn't growing quicker than they are. Azure has become a top platform for building AI applications, but has it done enough to make Microsoft a top buy now? Microsoft's stock is starting to look a bit pricey for its growth If Microsoft derived all of its revenue from Azure, I'd be a buyer at nearly any price. However, Microsoft has other product lines that aren't growing as quickly, which slows the company's overall growth pace. In its latest period -- the third quarter of fiscal 2025 -- overall revenue rose to $70.1 billion at a 13% pace. While Microsoft doesn't break out the revenue generated by Azure, we know from prior information that it accounts for over half of the Intelligent Cloud division, which brought in $26.8 billion during Q3 (ending March 31). They do provide Azure's growth rate, which was Microsoft's top-performing division in Q3, rising 33% year over year. Microsoft's diluted earnings per share also rose an impressive 18%, but is that fast enough to justify its valuation? Microsoft trades at nearly 40 times trailing earnings, which is a very expensive price tag and exceeds its recent highs reached during the AI arms race period. Wall Street analysts project $15.14 in earnings per share for fiscal 2026 (ending June 30, 2026), which indicates the stock trades at 33.7 times forward earnings. That's still a high valuation, and investors need to start being a bit cautious when stocks reach that level, especially when they're growing at Microsoft's pace. Yes, Microsoft is growing faster than the market, but it's not growing as fast as some of its peers. Take Meta Platforms, for example. It trades at 28 times trailing earnings and grew revenue at a 16% pace during its last quarter with 36% earnings-per-share growth. That's a cheaper stock growing faster, which should cause Microsoft investors to question whether it's the best big tech stock to be in right now. Numerous other big tech stocks have better growth numbers and cheaper valuations than Microsoft. Although it's a dominant company, it's starting to look a bit expensive compared to its peers. Should you buy stock in Microsoft right now? Before you buy stock in Microsoft, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Microsoft wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Keithen Drury has positions in Alphabet, Amazon, and Meta Platforms. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. 1 Super Artificial Intelligence (AI) Stock Billionaire Bill Gates Has 25% of His Foundation's Portfolio Invested In was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
28 minutes ago
- Yahoo
Better Beverage Stock: Coca-Cola vs. PepsiCo
Key Points Coca-Cola appears to have the edge when comparing recent stock performances. Investors should also take PepsiCo's valuation and dividend returns into account. 10 stocks we like better than PepsiCo › Although earnings season has barely started, both PepsiCo (NASDAQ: PEP) and its archrival, Coca-Cola (NYSE: KO), have already reported earnings for the second quarter of 2025. The waning popularity of soda beverages and, in PepsiCo's case, the falling demand for snack foods, have translated into anemic growth for both companies. One thing to remember about both stocks is that they have become popular among dividend investors, each maintaining a record of annual dividend hikes for more than half a century. Amid such conditions, one beverage stock may ultimately stand out as a more suitable choice for most investors. Comparing the two businesses Although a flagship cola product defines each stock, both companies are diversified beverage holdings. Each controls numerous brands under their umbrellas, and their selections encompass juices, coffees, teas, and waters. Additionally, both companies are now in the alcohol business. Coca-Cola entered this arena by offering Topo Chico hard seltzers, and PepsiCo has partnered with other companies to sell branded beverages like Hard Mountain Dew and Lipton Hard Iced Tea. Additionally, as previously mentioned, PepsiCo is in the snack business, owning such packaged food brands as Frito-Lay and Quaker. Unfortunately for both companies, a nutrition-inspired pivot has impacted sales, and this is particularly true of PepsiCo, whose customers are increasingly seeking healthier snack options. To that end, both companies have agreed with the Trump administration to produce cane sugar versions of their flagship colas, as more consumers turn away from high-fructose corn syrup. How the numbers compare However, such initiatives have not yet translated into higher sales. Furthermore, healthier ingredients often cost more, which will inevitably lead to higher input costs. As a result, both companies reported Q2 revenue increases of 1%, with price increases offsetting a slight drop in sales. From there, the results diverge, at least initially. Coca-Cola's Q2 net income was $3.8 billion, up from $2.4 billion in the year-ago quarter. Other operating charges fell from almost $1.4 billion in Q2 2024 to just $71 million one year later, accounting for nearly all of the improvement. In contrast, PepsiCo's $1.3 billion in Q2 net income was down from $3.1 billion 12 months ago. Still, if not for the $1.9 billion impairment charge on intangibles, net income would have narrowly increased. Thus, without one-time charges, the results seem to closely approximate each other. Even with their numerous similarities, Coca-Cola's stock has outperformed PepsiCo's over the previous year. However, that outperformance does not necessarily make Coca-Cola the clear choice, even though Coca-Cola's P/E ratio of 28 is not significantly higher than PepsiCo's 27 earnings multiple. When comparing forward P/E ratios (which exclude one-time charges), PepsiCo's 18 forward price-to-earnings ratio is considerably lower than Coca-Cola's, a stock which trades at a forward P/E ratio of 23. Furthermore, PepsiCo may stand out with dividend investors. Both stocks are Dividend Kings by virtue of their long-established track records of annual payout hikes. Still, PepsiCo's dividend yield of almost 3.8% far outpaces Coca-Cola's at around 2.9%, arguably making PepsiCo a better fit for income investors. Coca-Cola or PepsiCo? As for which stock to choose, investors do not have a bad choice in the sense iconic brands will likely drive rising sales for both companies for years to come. However, if you're buying today, PepsiCo appears to offer a slight edge to shareholders. Admittedly, both stocks have offered growth and income to their long-term investors, and that is unlikely to change. Also, Coca-Cola's more recent outperformance may tempt investors to choose it. Nonetheless, both are mature, slower-growth companies, and that makes PepsiCo's attributes stand out. For one, since PepsiCo operates in both the beverage and snack industries, it offers a greater degree of revenue diversification. Also, while financial results appear similar in most respects, PepsiCo's forward P/E ratio suggests it is the lower-cost stock after factoring in one-time charges. Finally, thanks in part to a lower valuation, PepsiCo offers investors higher dividend returns. Since investors tend to buy these stocks for income, PepsiCo is probably the more suitable choice in most cases. Should you buy stock in PepsiCo right now? Before you buy stock in PepsiCo, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and PepsiCo wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Will Healy has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Better Beverage Stock: Coca-Cola vs. PepsiCo was originally published by The Motley Fool
